研究单位：[1]Xuanwu Hospital, Capital Medical University,Beijing,Beijing,China,100053[2]Beijing Joekai Biotechnology LLC[3]Beijing Anding Hospital, Capital Medical University,Beijing,Beijing,China[4]Beijing Friendship Hospital, Capital Medical University,Beijing,Beijing,China[5]Beijing Tiantan Hospital, Capital Medical University,Beijing,Beijing,China[6]Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,Guangzhou,Guangdong,China[7]Wuhan Union Hospital of China,Wuhan,Hubei,China[8]The First affiliated hospital of SOOCHOW university,Suzhou,Jiangsu,China[9]The First Bethune Hospital of Jilin University,Chang chun,Jilin,China[10]Ruijin Hospital, Shanghai Jiaotong University School,Shanghai,Shanghai,China[11]Tianjin Huanhu Hospital,Tianjin,Tianjin,China[12]Sir Run Run Shaw Hospital,Hangzhou,Zhejiang,China
This is a multi-center, Phase IIa, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety of two doses of 50561 compared to placebo in participants diagnosed with mild to moderate Alzheimer's disease.
